Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Life sciences venture capital firm Forbion says that its newest portfolio company, Prilenia Therapeutics, a Naarden, Netherlands- and Herzliya, Israel-based clinical stage biotech company, has raised $62.5 million in a Series A financing round. 4 June 2020
Biotechnology
Of around 50 biopharma companies and contract manufacturing organizations that took advantage of a US government $659 billion loan program, five are working on COVID-19 therapies. 3 June 2020
Biotechnology
Interleukin (IL)-17A antagonist Taltz (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data to be presented virtually on June 5 at the European Congress of Rheumatology 2020 (EULAR). 3 June 2020
Biotechnology
US pharma major Bristol-Myers Squibb today announced results from the open-label switch period of Early AMPLE, a Phase IV exploratory biomarker study assessing the differences by which Orencia (abatacept) and another treatment, adalimumab, interfere with disease progression in moderate-to-severe early rheumatoid arthritis (RA) patients who tested positive (seropositive) for certain autoantibodies. 3 June 2020
Biotechnology
China-based biotech BeiGene today revealed that its BTK inhibitor Brukinsa(zanubrutinib) has received approval from the China National Medical Products Administration (NMPA) in two indications. 3 June 2020
Biotechnology
US biotech Regeneron Pharmaceuticals has failed to invalidate a fifth Kymab patent, covering genetically-modified mice used to produce human antibody therapeutics. 3 June 2020
Biotechnology
Novo Ventures, part of Denmark’s Novo Holdings, today announced that it has led the $55 million Series B financing in UK and USA-based biotech NodThera, which is developing a new class of medicines to treat diseases driven by chronic inflammation. Nanna Lüneborg, a partner at Novo Ventures, will join the NodThera board. 3 June 2020
Biotechnology
Swiss biotech Relief Therapeutics and its US partner, NeuroRx, have announced the start of treatment of patients with RLF-100 at the University of Miami Miller School of Medicine. 3 June 2020
Biotechnology
Pfizer, at a time when the COVID-19 pandemic is disrupting drugmakers clinical trials activities, on Tuesday announced the establishment of the Pfizer Breakthrough Growth Initiative, through which the US pharma giant will invest up to $500 million in biotechnology companies to help provide funding and access to Pfizer’s scientific expertise to ensure continuity of the biotechnology companies’ most promising clinical development programs. 3 June 2020
Biotechnology
Danish dermatology specialist LEO Pharma has promised a plethora of data from Phase III trials in atopic dermatitis (AD) and psoriasis at this year’s American Academy of Dermatology (AAD) virtual meeting later this month. 2 June 2020
Biotechnology
The European Commission (EC) has approved Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. 2 June 2020
Biotechnology
Bristol-Myers Squibb has announced more news on its immunomodulatory drug Zeposia (ozanimod). 2 June 2020
Biotechnology
The US Department of Health and Human Services (HHS) has added $628 million to its contract with Emergent BioSolutions to advance manufacturing capabilities and capacity for a potential COVID-19 vaccine as well as therapeutics. 2 June 2020
Biotechnology
R-Pharm Group of companies, one of Russia’s leading biotech companies, has officially completed registration the of Artlegia (olokizumab), a new drug which is initially designed for treatment of rheumatoid arthritis but which could be potentially recommended for the treatment of severe forms of COVID-19, according to the company. 2 June 2020
Biotechnology
Following a positive recommendation from the US regulator’s advisory panel, Cyramza (ramucirumab) has picked up a sixth approval, in a first-line lung cancer treatment setting. 2 June 2020
Biotechnology
Applications for a new indication have been submitted to the US Food and Drug Administration and European Medicines Agency for Rinvoq (upadacitinib) 15mg, once daily, a selective and reversible JAK inhibitor, for the treatment of adult patients with active psoriatic arthritis, by US biopharma major AbbVie. 2 June 2020
Biotechnology
Eli Lilly and AbCellera have begun a Phase I study of LY-CoV555, a potential antibody treatment designed to fight COVID-19. 2 June 2020
Biotechnology
Regeneron and Sanofi have presented new data on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (CSCC), the deadliest non-melanoma skin cancer. 1 June 2020
Biotechnology
Updated analysis of the Phase III CASPIAN trial showed Imfinzi (durvalumab) alongside a choice of chemotherapies demonstrated a sustained, clinically-meaningful overall survival (OS) benefit as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). 1 June 2020
Biotechnology
The US Food and Drug Administration has approved a supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) injection 80mg/mL for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation. 1 June 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze